Acrivon Therapeutics (ACRV) Stock Price, Quote, News & History | Benzinga

Acrivon Therapeutics Inc (ACRV) Stock Price, Quote, News & History

ACRVNASDAQ

Trade with Public

Trade with Public

$1.85

-0.065-3.39%

Last update: May 15, 10:13 AM

Earnings: Q1 2026 Earnings were released on Wed May 13th, after the market close

OverviewNews Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$1.88

Close

-

Volume / Avg.

124.12K / 783.70K

Day Range

$1.80 - $1.90

52 Wk Range

1.05 - 3.56

Market Cap

$79.40M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

8.6%

Days to Cover

2.29

Recent Acrivon Therapeutics Inc News

Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls

Acrivon Therapeutics shares new trial data showing strong cancer responses, early tumor shrinkage, and pipeline progress, while confirming cash runway into 2027.

Vandana Singh

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free

Avi Kapoor

Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?

Acrivon Therapeutics has entered into a securities purchase agreement to issue and sell 8.235 million shares of its common stock at a price of $8.50 per share, as well as pre-funded warrants to purchase up to 7.06 million shares through a private investment in public equity (PIPE) financing.

Adam Eckert

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-64.67M

Investing Cash Flow (TTM)

60.01M

Financing Cash Flow (TTM)

-439.00K

Free Cash Flow (TTM)

-66.29M

Capital Expenditure (TTM)

-1.63M

Net Change in Cash (TTM)

-5.09M

Analyst Trends and Forecast

1

Nov 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$13.14M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.86

Earnings Yield % (TTM)

-104.17%

Earnings Yield % (FWD)

-111.46%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.23

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$34.06M

Debt to Equity

0.03

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.88

Close

-

Volume / Avg.

124.12K / 783.70K

Day Range

$1.80 - $1.90

52 Wk Range

1.05 - 3.56

Market Cap

$79.40M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

8.6%

Days to Cover

2.29

About

Sector

Health Care

Industry

Biotechnology

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient resp...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Acrivon Therapeutics (ACRV) stock?

A

You can purchase shares of Acrivon Therapeutics (NASDAQ:ACRV) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Acrivon Therapeutics (ACRV) competitors?

A

There are no as such competitors for Acrivon Therapeutics.

Q

What is the forecast, or price target, for Acrivon Therapeutics (ACRV) stock?

A

Acrivon Therapeutics has a consensus price target of $19.20.

Q

What is the current price for Acrivon Therapeutics (ACRV)?

A

The stock price for Acrivon Therapeutics (NASDAQ: ACRV) is $1.855 last updated May 15, 2026 at 10:13 AM EDT.

Q

Does Acrivon Therapeutics (ACRV) pay a dividend?

A

There are no upcoming dividends for Acrivon Therapeutics.

Q

When is Acrivon Therapeutics (NASDAQ:ACRV) reporting earnings?

A

Acrivon Therapeutics does not have any upcoming earnings scheduled.

Q

Is Acrivon Therapeutics (ACRV) going to split?

A

There is no upcoming split for Acrivon Therapeutics.

Q

What sector and industry does Acrivon Therapeutics (ACRV) operate in?

A

Acrivon Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.